Literature DB >> 29230150

Nonmedical Switching of Biosimilars in Patients With Inflammatory Bowel Disease.

Russell D Cohen1.   

Abstract

Entities:  

Year:  2017        PMID： 29230150      PMCID： PMC5717886     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.

Authors:  Bente Glintborg; Inge Juul Sørensen; Anne Gitte Loft; Hanne Lindegaard; Asta Linauskas; Oliver Hendricks; Inger Marie Jensen Hansen; Dorte Vendelbo Jensen; Natalia Manilo; Jakob Espesen; Mette Klarlund; Jolanta Grydehøj; Sabine Sparre Dieperink; Salome Kristensen; Jimmi Sloth Olsen; Henrik Nordin; Stavros Chrysidis; Dorte Dalsgaard Pedersen; Michael Veedfald Sørensen; Lis Smedegaard Andersen; Kathrine Lederballe Grøn; Niels Steen Krogh; Lars Pedersen; Merete Lund Hetland
Journal:  Ann Rheum Dis       Date:  2017-05-04       Impact factor: 19.103

2.  Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Authors:  Kristin K Jørgensen; Inge C Olsen; Guro L Goll; Merete Lorentzen; Nils Bolstad; Espen A Haavardsholm; Knut E A Lundin; Cato Mørk; Jørgen Jahnsen; Tore K Kvien
Journal:  Lancet       Date:  2017-05-11       Impact factor: 79.321

3.  The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.

Authors:  C E M Griffiths; D Thaçi; S Gerdes; P Arenberger; G Pulka; K Kingo; J Weglowska; N Hattebuhr; J Poetzl; H Woehling; G Wuerth; M Afonso
Journal:  Br J Dermatol       Date:  2017-03-01       Impact factor: 9.302

4.  Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease.

Authors:  Lisa J T Smits; Anna Grelack; Lauranne A A P Derikx; Dirk J de Jong; Aura A J van Esch; Ronald S Boshuizen; Joost P H Drenth; Frank Hoentjen
Journal:  Dig Dis Sci       Date:  2017-06-30       Impact factor: 3.199
  4 in total
  1 in total

Review 1.  Biosimilars: Science, Implications, and Potential Outlooks in the Middle East and Africa.

Authors:  Radwa Ahmed Batran; Mai Elmoshneb; Ahmed Salah Hussein; Omar M Hussien; Fady Adel; Reham Elgarhy; Mosaad I Morsi
Journal:  Biologics       Date:  2022-10-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.